{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
alpha-tocopherol
to a specific field?
Status:
Investigational
Source:
INN:nobiprostolan [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Mallinckrodt (previously Sucampo Pharmaceuticals) is developing nobiprostolan (RK 023), a topical therapy for male pattern baldness (androgenetic alopecia) and hypotrichosis. The drug is a physiologically active fatty acid derivative. Nobiprostolan is in Phase IIa clinical trials for the treatment of male pattern baldness.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
DICHLORISONE is a synthetic corticosteroid used topically for its glucocorticoid activity in the treatment of various skin disorders.
Status:
Investigational
Source:
NCT03396068: Phase 3 Interventional Active, not recruiting Bipolar Depression
(2019)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
NCT03397134: Phase 3 Interventional Completed Negative Symptoms of Schizophrenia
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
CYR-101 (MIN-101) is a cyclic amide derivative that has high equipotent affinities for 5-HT2A and sigma-2 receptors (Ki of 7.53 nM and 8.19 nM for 5-HT2A and sigma-2, respectively). MIN-101 also shows binding affinity for a1-adrenergic receptors but low or no affinity for muscarinic, cholinergic, and
histaminergic receptors. MIN-101 demonstrated statistically significant efficacy in reducing negative symptoms and good tolerability in stable schizophrenia patients. The drug is in phase II clinical trials for the treatment of Schizophrenia.
Status:
Investigational
Source:
NCT00695448: Phase 1 Interventional Terminated Solid Tumours
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
GSK 1059615, a pyridinylquinoline derivative, is a novel PI3K kinase and mTOR dual inhibitor. GSK1059615 was in phase I clinical trial in patients with solid tumors or lymphoma, but this study was terminated prematurely due to lack of sufficient exposure following single- and repeat dosing. In addition, recently was shown, that GSK 1059615 in xenograft mice models possessed anti-head and neck squamous cell carcinoma (HNSCC) cell activity.
Status:
Investigational
Source:
NCT01802320: Phase 2 Interventional Completed Colon Mucinous Adenocarcinoma
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
MK-2206 is an oral selective allosteric inhibitor of Akt that targets all three isoforms of human Akt (Akt-1, Akt-2 and Akt-3). In a phase I study of solid tumors, MK-2206 demonstrated evidence of target modulation and anti-proliferative activity as a single agent and in combination with other agents. Current ongoing trials of MK-2206 include monotherapy and combination therapy in breast cancer, colorectal cancer, haematological malignancies, non-small cell lung cancer and other. Detected treatment-related adverse event are: rash, fatigue, hyperglycemia.
Class (Stereo):
CHEMICAL (ACHIRAL)
Quinazosin is a diaminoquinazoline derivative patented by Pfizer, Chas., and Co., Inc. as a hypotensive agent. Quinazosin acts as adrenoreceptor antagonist and in preclinical studies lowered systolic blood pressure in conscious hypertensive dogs, without having any significant effect on their heart rate. Quinazosin lowered blood pressure and reduced total peripheral vascular resistance, while the duration of these effects was dose-dependent. In cats, Quinazosin reduced or reversed the pressor effects of epinephrine, but did not alter those of angiotensin amide.
Status:
Investigational
Source:
NCT00385489: Phase 1 Interventional Completed Healthy
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
LXR-623 is a is a highly selective and orally bioavailable synthetic agonist of Liver X receptors (LXR) alpha and beta that has shown promise in animal models of atherosclerosis. In nonhuman primates with normal lipid levels, LXR-623 significantly reduced total (50-55%) and LDL-cholesterol (LDLc) (70-77%) in a time- and dose-dependent manner and increased expression of the target genes ABCA1 and ABCG1 in peripheral blood cells of rats, mice and monkeys. LXR-623 demonstrated efficacy for reducing lesion progression in the murine LDLR(-/-) atherosclerosis model with no associated increase in hepatic lipogenesis either in this model or Syrian hamsters and displayed a unique and favorable pharmacological profile suggesting it may be suitable for evaluation in patients with atherosclerotic dyslipidemia. Results from a single ascending-dose study of the safety, pharmacokinetics, and pharmacodynamics of LXR-623 in healthy humans confirmed the effect of LXR-623 concentration on ABCA1 and ABCG1 expression. LXR-623 was absorbed rapidly with peak concentrations (Cmax) achieved at about 2 hours and increased Cmax and area under the concentration-time curve in a dose-proportional manner. The mean terminal disposition half-life was between 41 and 43 hours independently of dose. Central nervous system—related adverse events were observed at the 2 top doses tested. LXR-623 showed brain penetration and caused tumor regression in a glioblastoma (GBM) mouse model which characterize it as a potentially potent, highly-specific anti-GBM therapy.
Status:
Investigational
Source:
NCT00552565: Phase 3 Interventional Completed Irritable Bowel Syndrome With Diarrhea
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Arverapamil (brand name Rezular), a modulator of melatonin and serotonin receptors, was developed by Ireland-based company, AGI Therapeutics. The drug participated in phase III of clinical trials for patients to treat the irritable bowel syndrome with diarrhea, the trial was discontinued because the drug didn’t meet the primary endpoint.
Status:
Investigational
Source:
INN:dioxaphetyl butyrate [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Dioxaphetyl butyrate is a synthetic narcotic analgesic and spasmolytic agent that has no accepted medicinal value in the United States. This opioid drug under international control according to the UN Single Convention 1961 and its amendments, Schedule I.
